Cardiology & Cardiovascular Research

Open Access

Abstract

Myocardial Revascularization – Where Do We Stand Through The Guidelines Window

Dragana Šarenac.

What is new in ESC and ACC revascularization guidelines. Why we need to embrace it in everyday practice. When we can use different antiplatelet therapeutic options in those patients. How can we implement mode of artificial intelligence after primary PCI. When and What is the right new definition of ACS. ESC 2023. new guideliness and urge for complete revascularization. ACC 2021. Main pathways Why and how to assess High Bleeding Risk (HBR), seen in about 20% of ACS patients. Can we measure periprocedural risk in ACS and what types of de-escalation antiplatelet therapy can be used.

CCS – Chronic coronary sydrom (stable angina) ESC 2019. guidelines. ACC 2023. What are patient risk profiles number 1, 2 and 3. Why we should use Guideline Directed Medical Therapy, the proven benefit in CCS. Different types of revascularization therapies, OMT (Optimal Medical Therapy) vs PCI vs CABG (Coronary Artery By Pass). What is OPTIMUM Registry and who are the patients ineligible for surgical revascularization. The role and definition of Prehabilitation. All those new aspects through intertwined evidence based cardiology facts concerning revascularization, across both side of the ocean.

Citation: Dragana Šarenac.. Myocardial Revascularization – Where Do We Stand Through The Guidelines Window. Cardiol Cardiovasc Res. 2024; 2(3):1-9. DOI: 10.52106/2996-3885.1015.
View PDF